When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BeyondSpring (BYSI-0.8%) announces that its PROTECTIVE-2 (Study 106) Phase 2 superiority trial for chemotherapy-induced neutropenia (CIN) shows that Plinabulin, in combination with Neulasta improves dose and regimen compliance in patients treated with docetaxel, doxorubicin and cyclophosphamide (TAC Chemotherapy) compared to Neulasta alone.
More news on: BeyondSpring Inc., Healthcare stocks news,